Proteolytic Processing of Stat6 Signaling in Mast Cells as a Negative Regulatory Mechanism by Suzuki, Kotaro et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/07/27/12 $5.00
Volume 196, Number 1, July 1, 2002 27–38
http://www.jem.org/cgi/doi/10.1084/jem.20011682
 
27
 
Proteolytic Processing of Stat6 Signaling in Mast Cells as a 
Negative Regulatory Mechanism
 
Kotaro Suzuki,
 
1 
 
Hiroshi Nakajima,
 
1 
 
Shin-ichiro Kagami,
 
1 
 
Akira Suto,
 
1 
 
Kei Ikeda,
 
1 
 
Koichi Hirose,
 
1 
 
Takaki Hiwasa,
 
2 
 
Kiyoshi Takeda,
 
3
 
Yasushi Saito,
 
1 
 
Shizuo Akira,
 
3 
 
and Itsuo Iwamoto
 
1
 
1
 
Department of Internal Medicine II and 
 
2
 
Department of Biochemistry and Genetics, Graduate School of Medicine, 
Chiba University, Chiba 260-8670, Japan
 
3
 
Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, 
Osaka 565-0871, Japan
 
Abstract
 
Accumulating evidence has shown the importance of Stat6-mediated signaling in allergic dis-
eases. In this study, we show a novel regulatory mechanism of Stat6-mediated signaling in mast
cells. When Stat6 is activated by interleukin (IL)-4 and translocated to the nucleus, Stat6 is
cleaved by a nucleus-associated protease in mast cells. The cleaved 65-kD Stat6 lacks the
COOH-terminal transactivation domain and functions as a dominant-negative molecule to
Stat6-mediated transcription. The retrovirus-mediated expression of cleavage-resistant Stat6
mutants prolongs the nuclear accumulation of Stat6 upon IL-4 stimulation and enhances IL-4–
induced gene expression and growth inhibition in mast cells. These results indicate that the
proteolytic processing of Stat6 functions as a lineage-specific negative regulator of Stat6-depen-
dent signaling in mast cells, and thus suggest that it may account for the limited role of Stat6 in
IL-4 signaling in mast cells.
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Introduction
 
IL-4 is a multifunctional cytokine that plays a critical role
in the regulation of immune responses (1). Its effects de-
pend upon binding to and signaling through a receptor
 
complex consisting of the IL-4R
 
  
 
chain and either the
common cytokine receptor 
 
 
 
 chain (
 
 
 
c) or IL-13R
 
  
 
1
chain, resulting in a series of phosphorylation events me-
 
diated by receptor-associated Janus kinases (JAKs;
 
*
 
 refer-
ence 2). Among downstream molecules of JAKs, Stat6 acts
as a direct connection between the cytokine receptor and
the transcription apparatus (3). Stat6 is critical in the en-
hanced expression of many IL-4–responsive genes, includ-
ing class II major histocompatibility molecules, low affin-
ity IgE receptor (CD23), and IL-4R
 
  
 
chain (2). Recent
 
studies with Stat6-deficient (Stat6
 
 
 
/
 
 
 
) mice also show that
the Stat6 pathway is the principal signaling pathway in-
volved in the commitment of CD4
 
  
 
T cells to the Th2
phenotype and IgE isotype switching in B cells (4–6). Al-
though the role and the positive regulatory mechanisms of
Stat6 activation are well documented, little is known
about the mechanisms involved in the down-regulation of
Stat6-dependent signaling.
Mast cells are recognized as the major effector cells of
type I hypersensitivity reactions and play a pivotal role in
allergic diseases such as asthma, allergic rhinitis, and atopic
dermatitis (7). IL-4 is a potent growth factor of mast cells in
human (8) and mouse (9), although in some situations IL-4
enhances the apoptosis of mast cells (10). Stat6 is not essen-
tial for IL-4–induced proliferation of bone marrow–
derived mast cells (BMMCs; reference 11), whereas Stat6 is
essential for IL-4–induced proliferation of T cells (4–6). On
the other hand, it has recently been shown, especially in
the presence of IL-10, that IL-4 induces the apoptosis of
IL-3–dependent mast cells by Stat6-dependent signaling
(10). In addition, intestinal mastcytosis induced by parasitic
infection is enhanced in Stat6
 
 
 
/
 
  
 
mice (12). Recently, we
and others have shown that a short isoform of Stat6 (65-kD
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Mast Cell–specific Cleavage of Stat6
 
Stat6) is expressed in mast cells (13, 14). However, the
mechanism of 65-kD Stat6 production as well as the role of
65-kD Stat6 in mast cells remains to be determined.
In this study, we show a novel regulatory mechanism of
Stat6-mediated signaling in mast cells. When Stat6 is acti-
vated by IL-4 and translocated to the nucleus, Stat6 is
cleaved at the COOH terminus by a nucleus-associated
protease in mast cells. The cleaved 65-kD Stat6 lacks the
transcriptional activity and acts as a dominant-negative
molecule to conventional Stat6-mediated transcription.
The Stat6 protease activity is sensitive to serine protease
inhibitors, but different from previously described Stat5
protease in myeloid progenitors (15–18). Moreover, the
retrovirus-mediated expression of cleavage-resistant Stat6
mutants prolongs the nuclear accumulation of Stat6 upon
IL-4 stimulation and enhances IL-4–induced gene expres-
sion and growth inhibition in mast cells. Our results indi-
cate that the proteolytic processing of Stat6 functions as a
lineage-specific negative regulator of Stat6-dependent sig-
naling in mast cells.
 
Materials and Methods
 
Mice.
 
Stat6-deficient (Stat6
 
 
 
/
 
 
 
) (4) and C57BL/6 mice (Ja-
pan SLC) were housed in microisolator cages under pathogen-
free conditions. All experiments were performed according to the
guidelines of Chiba University (Chiba, Japan).
 
Constructs.
 
Flag epitope–tagged Stat6 at the COOH terminus
(C-Flag Stat6) was constructed as previously described (19).
COOH-terminal–truncated mutants at amino acid (aa) 673 (673
Stat6), aa 695 (695 Stat6), or aa 715 (715 Stat6) were generated by
changing each aa to a stop codon by using a PCR-based, site-
directed mutagenesis kit (Stratagene). Alanine substitutions of Stat6
on serine at aa 683 (S683A), serine at aa 684 (S684A), aspartic acid
at aa 685 (D685A), or methionine at aa 686 (M686A) were gen-
erated by using a PCR-based, site-directed mutagenesis kit (Strat-
agene). All mutations were confirmed by DNA sequencing.
 
Culture of BMMCs.
 
Primary culture of IL-3–dependent
BMMCs was prepared from 8–12-wk-old C57BL/6 or Stat6
 
 
 
/
 
 
 
mice and maintained as previously described (13). BMMCs ob-
tained after 4 wk of culture were 
 
 
 
99% mast cells.
 
Luciferase Assay.
 
Stat6-dependent reporter construct, TPU474,
was previously described (20). For Stat6-dependent luciferase as-
says, COS7 cells were transiently transfected with TPU474 (pro-
vided by U. Schindler, Tularik Inc., San Francisco, CA) and
pRL-TK in the presence of various Stat6 expression vectors alone
or in their combinations using FuGENE6 transfection reagents
(Roche Diagnostics Co.). 20 h after transfection, cells were stim-
ulated with IL-4 (human IL-4, 10 ng/ml; Genzyme) at 37
 
 
 
C for
an additional 12 h and the luciferase activity was measured by the
dual luciferase assay system (Promega). Firefly luciferase activity
of TPU474 was normalized by Renilla luciferase activity of
pRL-TK.
 
Preparation of Cell Extracts.
 
Cell fractionation was performed as
follows. All buffers were added to these reagents: 1 mM Na
 
3
 
VO
 
4
 
,
5 
 
 
 
g/ml aprotinin, 5 
 
 
 
g/ml leupeptin, 2 
 
 
 
g/ml pepstatin, and
0.5 mM PMSF. For the preparation of whole cell extracts, cells
were resuspended in lysis buffer W (1% NP-40, 20 mM Tris-
HCl, pH 8.0, 50 mM NaCl, 2 mM DTT, 4 mM EGTA, 10 mM
NaF, and 10% glycerol), incubated on ice for 30 min, and then
the supernatant was collected by centrifugation. Nuclear or cyto-
 
plasmic fraction of cells was prepared as previously described (21).
In brief, after 10
 
7 
 
cells were washed with PBS, cells were resus-
pended in 100 
 
 
 
l hypotonic lysis buffer A (0.1% NP-40, 10 mM
Hepes-KOH, pH 7.9, 10 mM KCl, 1 mM DTT, 0.1 mM
EDTA, 2 mM MgCl
 
2
 
, and 0.5 M sucrose) and lysed by 10 strokes
in a glass Dounce homogenizer. The supernatant was collected as
a cytoplasmic fraction by centrifugation. Subsequently, nuclear
fraction was prepared by resuspending nuclear pellets with 15 
 
 
 
l
high salt lysis buffer C (20 mM Hepes-KOH, pH 7.9, 420 mM
NaCl, 1 mM DTT, 0.2 mM EDTA, 1.5 mM MgCl
 
2
 
, and 5%
glycerol). The nuclear fraction was then mixed with 22.5 
 
 
 
l of a
low salt buffer (20 mM Hepes-KOH, pH 7.9, 50 mM KCl, 1
mM DTT, 0.2 mM EDTA, and 20% glycerol). The purity of the
extracts was evaluated by measuring lactate dehydrogenase activ-
ity and we found that the nuclear extract contained 
 
 
 
5% of con-
tamination (unpublished data). In addition, NaCl concentration
of cytoplasmic extract as well as nuclear extract was adjusted to
150 mM before Stat6 cleaving assay. In some experiments, sple-
nocytes or BMMCs were stimulated with IL-4 (10 ng/ml) at
37
 
 
 
C for 20 min before the preparation of cell extracts. In other
experiments, BMMCs were starved from IL-3 for 5 h and then
stimulated with IL-3 (10 ng/ml; Genzyme) at 37
 
 
 
C for 20 min
before preparing cell extracts.
 
Stat6 Cleaving Assay.
 
Stat6 protein from either wild-type
(WT) splenocytes or murine Stat6 expression vector-transfected
COS7 cells (provided by J.N. Ihle, St. Jude Children’s Hospital,
Memphis, TN) was incubated with cell extracts from Stat6
 
 
 
/
 
 
 
BMMCs at 37
 
 
 
C for 20 min. Where indicated, 
 
p
 
-chloromer-
curibenzoate (PCMB; 0.1 mM; Wako Pure Chemical Industries),
matrix metalloproteinase (MMP) inhibitor I (4-Abz-Gly-Pro-D-
Leu-D-Ala-OH; 0.1 mM; Calbiochem-Novabiochem), lactacys-
tin (clasto-lactacystin-
 
 
 
-lactone; 1 
 
 
 
M; Boston Biochem), z-VAD
(z-VAD-FMK; 0.1 mM; Calbiochem-Novabiochem), ICE in-
hibitor III (z-Asp-2,6-dichlorobenzoyloxymethylketone; 0.1 mM;
Funakoshi), ALLN calpain inhibitor I (
 
N
 
-acetyl-Leu-Leu-nor-
leucinal; 0.1 mM; Calbiochem-Novabiochem), or 4-(2-aminoethyl)-
benzenesulfonyl fluoride hydrochloride (AEBSF; 0.3–16 mM;
Roche Diagnostics Co.) was added during the incubation. The
reaction was separated on 10% SDS polyacrylamide gels and sub-
jected to Western blotting as described below.
 
Stat5 Cleaving Assay.
 
After WT BMMCs or FDC-P1 cells
(provided by T. Kitamura, University of Tokyo, Tokyo, Japan)
were starved from IL-3 for 5 h, nuclear extracts were prepared as
described above. COS7 cells were transfected with murine Stat5a
expression vector (provided by L. Hennighausen, National Insti-
tutes of Health [NIH], Bethesda, MD) and the extract was incu-
bated with nuclear extract from either WT BMMCs or FDC-P1
cells at 37
 
 
 
C for 20 min. The reaction was terminated by SDS
sample buffer, separated on 6% polyacrylamide gels, and sub-
jected to Western blotting as described below.
 
Western Blotting.
 
Immunoblotting was performed as previ-
ously described (13) using antisera to mouse Stat6 (M20; Santa
Cruz Biotechnology Inc.), mouse Stat6 (M200; Santa Cruz Bio-
technology Inc.), phospho-Stat6 (New England Biolabs, Inc.),
mouse Stat5 (Transduction Laboratories), phospho-Stat5 (New
England Biolabs, Inc.), human Stat3 (Upstate Biotechnology), or
Flag-epitope tag (M2; Sigma-Aldrich).
 
Retrovirus-mediated Gene Expression in BMMCs.
 
To overcome
the limited efficiency of transfection on BMMCs, we used a bi-
cistronic retrovirus system, in which infected cells were identified
by coexpressed green fluorescent protein (GFP; pMX-internal ri-
bosome entry site [IRES]-GFP vector; reference 22) or coex-
pressed Thy1.1 (murine stem cell virus [MSCV]-IRES-Thy1.1 
29
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vector; reference 23). Retrovirus vectors, pMX-WT Stat6-
IRES-GFP, pMX-D685A Stat6-IRES-GFP, pMX-673 Stat6-
IRES-GFP, pMX-IRES-GFP (as a negative control; provided by
T. Kitamura), MSCV-C-Flag WT Stat6-IRES-Thy1.1, MSCV-
C-Flag D685A Stat6-IRES-Thy1.1, and MSCV-IRES-Thy1.1
(as a negative control; provided by P. Marrack, University of
Colorado Medical School, Denver, CO) were transfected to a
transient retrovirus packaging cell line PlatE (provided by T. Ki-
tamura; reference 24) using FuGENE6 transfection reagents. 48 h
after transfection, retrovirus was collected by centrifugation and
stored at 
 
 
 
80
 
 
 
C until use. For infection on BMMCs, cells were
incubated twice with 1,000 
 
 
 
l of the retrovirus for 4 h at a 48-h
interval in the presence of 10 ng/ml murine IL-3, 100 ng/ml
murine stem cell factor (provided by Kirin Brewery Co.,
Takasaki, Japan), and 10 
 
 
 
g/ml polybrene (Sigma-Aldrich). After
the cells were washed with PBS, they were allowed to grow in
fresh medium containing IL-3. Under these conditions, the effi-
ciency of infection to BMMCs was 5–10% in all viruses as as-
sessed by GFP
 
  
 
or Thy1.1
 
  
 
cells by FACS
 
®
 
.
 
Retrovirus-mediated Gene Expression in CFTL-15 Cells.
 
CFTL-15
cells (provided by M.A. Brown [Williams College, Williams-
town, MA] and W.E. Paul [NIH, Bethesda, MD]), a murine mast
cell line that expresses 65-kD Stat6 (25), were cultured in RPMI
1640 medium containing murine IL-3. CFTL-15 cells were in-
fected with retroviruses for 4 h in the presence of 10 ng/ml IL-3
and 10 
 
 
 
g/ml polybrene. The efficiency of infection to CFTL-15
cells was 
 
 
 
30%.
 
MACS Sorting of Thy1.1
 
  
 
Cells.
 
5 d after the retrovirus in-
fection, cells were incubated with biotin-conjugated anti-Thy1.1
antibody (OX-7; BD PharMingen), washed three times with
PBS, and then incubated with streptavidin magnetic microbeads
(Miltenyi Biotec). After washing, infected (Thy1.1
 
 
 
) cells were
positively collected using MACS RS
 
  
 
column (Miltenyi Biotec).
The purity of Thy1.1
 
  
 
cells was 
 
 
 
98%. Cytoplasmic extracts of
Thy1.1
 
  
 
cells were subjected to Western blotting with anti-Flag
antibody to evaluate the levels of retrovirus-mediated Stat6 ex-
pression in the infected cells.
 
Immunohistochemistry.
 
CFTL-15 cells were infected with
either MSCV-C-Flag WT Stat6-IRES-Thy1.1 retrovirus or
MSCV-C-Flag D685A Stat6-IRES-Thy1.1 retrovirus and in-
fected (Thy1.1
 
 
 
) cells were positively collected as described
above. As controls, COS7 cells were transiently transfected with
either C-Flag WT Stat6 or C-Flag D685A Stat6 expression plas-
mids using FuGENE6 transfection reagents. CFTL-15 cells and
COS7 cells were stimulated with 10 ng/ml murine IL-4 and 10
ng/ml human IL-4, respectively, at 37
 
 
 
C for 15 min, washed
with PBS, and then cultured with IL-4–free medium for an addi-
tional 45 or 165 min. Where indicated, to block nuclear export,
cells were incubated with 10 ng/ml leptomycin B (Sigma-
Aldrich) at 37
 
 
 
C from 60 min before IL-4 stimulation until har-
vest as previously described (26). At the indicated times after IL-4
stimulation, CFTL-15 cells were placed on glass microscope
slides using cytospin. Cells were fixed in methanol at 
 
 
 
20
 
 
 
C for
10 min and then in acetone at 
 
 
 
20
 
 
 
C for 1 min. After washing
with PBS, cells were incubated with PBS containing 3% bovine
serum albumin for 30 min and then with PBS containing 5%
donkey serum for 30 min at room temperature to block nonspe-
cific binding. Cells were then washed three times with PBS,
incubated with Cy3-conjugated anti-Flag antibody (M2; Sigma-
Aldrich) at room temperature for 1 h, and then washed an addi-
tional three times with PBS. Their nuclei were stained with
DAPI (4
 
 
 
-6-diamidino-2-phenylindole; Sigma-Aldrich) for 15
min at room temperature.
 
Detection of IgE Receptors on BMMCs.
 
The expression of IgE
receptors on BMMCs was analyzed by FACS
 
® 
 
using mouse anti–
DNP IgE and anti-IgE antibody as previously described (13).
 
Data Analysis.
 
Data are summarized as mean 
 
  
 
SD. The sta-
tistical analysis of the results was performed by the unpaired 
 
t
 
 test.
 
P
 
 values 
 
 
 
0.05 were considered significant.
 
Results
 
A 65-kD Isoform of Stat6 Is Produced by Proteolytic Process-
ing.
 
In previous reports, we and others have shown that a
65-kD isoform of Stat6 (65-kD Stat6) is expressed in
BMMCs (13, 14). The 65-kD Stat6 in BMMCs is detected
by anti-Stat6 (M200) antibody, which recognizes the mid-
dle portion of Stat6 (aa 280–480), but not by anti-Stat6
(M20) antibody, which recognizes the COOH terminus of
Stat6 (13, 14). In addition, when BMMCs are stimulated
with IL-4, the phosphorylated form of Stat6 is detected at
65 kD by anti-phospho Stat6 antibody, which recognizes
the tyrosine residue at aa 641 (Y641) of Stat6 (13). These
findings indicate that the 65-kD Stat6 lacks the COOH
terminus but contains the Y641, which is essential for the
homodimerization of Stat6 (3). To determine whether the
65-kD Stat6 is a product of protein processing, we first
performed the coincubation assay in which the conven-
tional 94-kD Stat6 from splenocytes was incubated with
cell extracts of BMMCs and analyzed for the size of Stat6
protein by anti-Stat6 Western blotting. To eliminate the
influence of endogenous Stat6 expression in BMMCs, we
prepared whole cell extracts from BMMCs in Stat6
 
 
 
/
 
 
 
mice (Stat6
 
 
 
/
 
  
 
BMMCs) as a possible source of the pro-
tease(s). Interestingly, when conventional Stat6 (94-kD
Stat6) was incubated with Stat6
 
 
 
/
 
  
 
BMMC extract, the
94-kD Stat6 was cleaved to 65 kD (Fig. 1 A, compare lanes
3 and 4). The cleaved Stat6 was detected by anti-Stat6
(M200) antibody (Fig. 1 A, top) but not by anti-Stat6
(M20) antibody (Fig. 1 A, bottom), suggesting that the
cleaved Stat6 also lacks the COOH terminus. These results
indicate that the 65-kD Stat6 is produced by the cleavage
of the 94-kD Stat6 in BMMCs.
To further analyze the Stat6 protease activity, we devel-
oped the Stat6 cleaving assay using transfected Stat6 as a
substrate of the protease (Fig. 1 B). COS7 cells were trans-
fected with Stat6 expression vector and the cell extracts of
these cells were incubated with Stat6
 
 
 
/
 
  
 
BMMC extract
and subjected to Western blotting using anti-Stat6 (M200)
antibody. Consistent with the above findings (Fig. 1 A), in-
cubation of the 94-kD Stat6 with Stat6
 
 
 
/
 
  
 
BMMC extract
decreased the size of Stat6 to 65 kD (Fig. 1 B, lane 7). In
contrast, incubation with cell extracts from either Stat6
 
 
 
/
 
 
 
thymocytes or Stat6
 
 
 
/
 
  
 
splenocytes did not change the size
of the 94-kD Stat6 (Fig. 1 B), indicating that Stat6 protease
activity is absent in thymocytes and splenocytes.
 
Stat6 Protease Activity Is Localized in the Nucleus.
 
Next,
we examined the subcellular localization of Stat6 protease
activity in BMMCs. Cell extracts were prepared from the
cytoplasmic or nuclear fraction of Stat6
 
 
 
/
 
  
 
BMMCs and
then incubated with 94-kD Stat6. Interestingly, 94-kD 
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Mast Cell–specific Cleavage of Stat6
 
Stat6 was cleaved to 65-kD Stat6 by the incubation with
nuclear extract but not with the cytoplasmic extract from
Stat6
 
 
 
/
 
  BMMCs (Fig. 2 A). To exclude the possibility that
the protease is normally in a protected cellular compart-
ment that is detergent or high salt soluble, we added NP-
40 or NaCl to the cytoplasmic fraction to the levels that we
used for whole cell or nuclear extract preparation (1% NP-
40 or 420 mM NaCl), and then examined the Stat6 pro-
tease activity. However, there was still no detectable Stat6
protease activity in the cytoplasmic fraction of BMMCs
(Fig. 2 A). These results indicate that Stat6 protease activity
is localized in the nucleus.
Stat6 has been shown to translocate to the nucleus only
after Stat6 is phosphorylated by JAK kinases (2, 3). There-
fore, we tested whether phosphorylated Stat6 was a sub-
strate of the Stat6 protease. When phosphorylated Stat6 in
IL-4–stimulated splenocytes was incubated with Stat6 / 
BMMC extract, the phosphorylated form of Stat6 was effi-
ciently cleaved to 65-kD Stat6 (Fig. 2 B, compare lanes 2
and 4). In addition, the unphosphorylated form of Stat6
was also cleaved to 65-kD Stat6 by Stat6 /  BMMC ex-
tract (Fig. 2 B, compare lanes 1 and 3). Thus, both phos-
phorylated and unphosphorylated forms of Stat6 are sensi-
tive to the Stat6 protease activity. However, the in vivo
substrate of Stat6 protease should be the phosphorylated
form of Stat6 because of the nuclear localization of Stat6
protease activity.
Because Stat6 protease activity is restricted in the nu-
cleus, it is possible that the conventional 94-kD Stat6 is
expressed in the cytoplasm of WT BMMCs. Indeed, 94-
kD Stat6 but not 65-kD Stat6 was found in the cytoplasm
of WT BMMCs (Fig. 2 C, lanes 3 and 4). In contrast to
the cytoplasm, Stat6 was detected at 65 kD in the nucleus
only after IL-4 stimulation (Fig. 2 C, lane 2). These results
indicate that Stat6 is normally produced as the conven-
tional 94-kD form and that after translocation to the nu-
cleus, 94-kD Stat6 is cleaved to 65-kD Stat6 by a nucleus-
associated protease.
Stat6 Protease Activity Is Inhibited by Serine Protease Inhibi-
tors. We next sought to classify the Stat6 protease in
BMMCs. Although a battery of protease inhibitors (Materi-
als and Methods) was routinely added to all buffers used in the
Figure 1. A 65-kD isoform of Stat6 is produced by proteolytic process-
ing. (A) Cell extracts from WT splenocytes were incubated with cell ex-
tracts of BMMCs from Stat6 /  mice at 37 C for 20 min and analyzed by
Western blotting with anti-Stat6 (M200) antibody (top) or anti-Stat6
(M20) antibody (bottom). As controls, cell extracts from WT BMMCs
and Stat6 /  BMMCs were blotted with anti-Stat6 antibodies. Represen-
tative blots from four independent experiments are shown. (B) COS7
cells were transfected with Stat6 expression vector and their cell extracts
were used as a source of Stat6 protein. Transfected Stat6 was incubated
with cell extracts of thymocytes, splenocytes, or BMMCs from Stat6 / 
mice at 37 C for 20 min and analyzed by Western blotting with anti-Stat6
(M200) antibody. A representative blot from four independent experi-
ments is shown.
Figure 2. Stat6 protease activity is localized in the nucleus. (A) Sub-
fraction of cell extracts (nuclear or cytoplasmic) was prepared from
Stat6 /  BMMCs. Where indicated, 1% NP-40 or 420 mM NaCl was
added to the cytoplasmic fraction. These extracts were then incubated
with transfected Stat6 at 37 C for 20 min and subjected to Western
blotting with anti-Stat6 (M200) antibody. (B) Cell extracts from IL-4–
stimulated or –unstimulated WT splenocytes were incubated with Stat6 / 
BMMC extract and blotted with anti–phospho-Stat6 antibody (top) or
anti-Stat6 (M200) antibody (bottom). (C) Subfraction of cell extracts was
prepared from either IL-4–stimulated or –unstimulated WT BMMCs and
blotted with anti–phospho-Stat6 antibody (top) or anti-Stat6 (M200) an-
tibody (bottom). As a control, cell extracts from IL-4–stimulated or
–unstimulated WT splenocytes were blotted with these antibodies.31 Suzuki et al.
preparation and analysis of cell extracts of BMMCs, none
of these effectively inhibited the observed proteolytic activ-
ity to Stat6. Thus, we examined the effect of other protease
inhibitors on the Stat6 cleaving activity in BMMCs. As
shown in Fig. 3 A, PCMB, MMP inhibitor I, lactacystin,
z-VAD-FMK (z-VAD), ICE inhibitor III, nor calpain in-
hibitor I inhibited the Stat6 protease activity of Stat6 / 
BMMC extract. Interestingly, however, Stat6 protease ac-
tivity was significantly inhibited by AEBSF, a serine pro-
tease inhibitor. The Stat6 protease activity was inhibited in
part by 4 mM AEBSF and completely by 16 mM AEBSF
(Fig. 3 B). These results suggest that the Stat6 protease be-
longs to the serine protease family. In addition, the Stat6
protease activity was also inhibited by a high concentration
(5 mM) of PMSF (unpublished data), another serine pro-
tease inhibitor, although 0.5 mM PMSF did not signifi-
cantly inhibit the Stat6 protease activity.
Stat6 Is Cleaved in the Nucleus of Living Mast Cells. To fur-
ther  show that IL-4–activated Stat6 is physiologically
cleaved by the protease in the nucleus of living mast cells,
the nuclear extract of IL-4–stimulated WT BMMCs was
prepared either in the presence of 16 mM AEBSF or in
preheated SDS sample buffer. These extracts were then
subjected to immunoblotting with anti-phospho Stat6 anti-
body. As shown in Fig. 3 C, 94-kD Stat6 was significantly
increased in these extracts, which indicates that a part of
Stat6 proteolysis occurred during the preparation of the ex-
tracts. However, 65-kD Stat6 was still observed in the nu-
clear extracts of IL-4–stimulated BMMCs. These results in-
dicate that Stat6 is cleaved by the Stat6 protease in the
nucleus of IL-4–stimulated living mast cells.
BMMC Extract Does Not Cleave Stat5. It has recently been
shown that Stat5 is cleaved by an undefined Stat5 protease
in myeloid progenitors (15–18). Although the characteris-
tics of Stat5 protease are still largely unknown, it has been
reported that Stat5 protease activity is inhibited by serine
protease inhibitors (15–17). To determine whether Stat6
protease is identical to Stat5 protease, we first analyzed the
size of Stat5 proteins (Stat5a and Stat5b) in whole cell
extracts of BMMCs. As shown in Fig. 4 A, BMMCs ex-
pressed only conventional forms of Stat5a and Stat5b. In ad-
dition, when BMMCs were stimulated with IL-3, phos-
phorylated Stat5 was detected at  94 kD by anti-phospho
Stat5a antibody (Fig. 4 A, top). Moreover, using FDC-P1
cells as a source of Stat5 protease (15–17), we examined the
substrate specificity of Stat6 and Stat5 protease. As shown in
Fig. 4 B, the nuclear extract from FDC-P1 cells cleaved 94-
kD murine Stat5a to 80 kD (Fig. 4 B, lane 5, top), whereas
the FDC-P1 extract did not cleave Stat6 (Fig. 4 B, lane 5,
bottom). In contrast, the nuclear extract from WT BMMCs
cleaved Stat6 but not Stat5 (Fig. 4 B, lane 4). In addition,
Stat6 was expressed as 94-kD Stat6 in whole cell extracts of
FDC-P1 cells (unpublished data). Taken together, although
both Stat6 and Stat5 protease have not been cloned yet,
these results indicate that Stat6 differs from Stat5 protease.
Stat6 Is Cleaved between aa 673 and 695. To determine
the cleavage site of Stat6, we prepared several COOH-ter-
minal–truncated mutants of Stat6, including 715 Stat6, 695
Figure 3. Stat6 protease activity is inhibited by serine protease inhibi-
tors. (A) Similar to Fig. 1 B, transfected Stat6 was incubated with Stat6 / 
BMMC extract. Where indicated, PCMB, MMP inhibitor I, lactacystin,
z-VAD, ICE inhibitor III, or calpain inhibitor I was added during the in-
cubation. All cell extracts were prepared in the presence of EGTA, aproti-
nin, leupeptin, pepstatin, and 0.5 mM PMSF. A representative blot from
four independent experiments is shown. (B) Similarly, the indicated con-
centrations of AEBSF were added during the incubation. (C) Nuclear ex-
tract was prepared from IL-4–stimulated WT BMMCs in the presence
(lane 3) or absence (lane 2) of 16 mM AEBSF. Nuclear extract was also
prepared by directly resuspending the nuclear pellets of IL-4–stimulated
WT BMMCs with preheated SDS sample buffer (lane 4). These extracts
were then subjected to Western blotting with anti-phospho Stat6 antibody.
Figure 4. BMMC extract cleaves Stat6 but not Stat5. (A) Cell extracts
from IL-3–stimulated WT BMMCs were blotted with either anti–phos-
pho-Stat5 (top) or anti–pan-Stat5 (bottom) antibody. (B) Either murine
Stat5a (top) or murine Stat6 (bottom) from transfected COS7 cells was
incubated with nuclear extract from either WT BMMCs or FDC-P1
cells. Reactions were separated on 6 or 10% polyacrylamide gels and sub-
jected to Western blotting with anti-pan Stat5 antibody (top) or anti-
Stat6 (M200) antibody (bottom).32 Mast Cell–specific Cleavage of Stat6
Stat6, and 673 Stat6. These mutants were expressed in
COS7 cells and the extracts were subjected to coincubation
assay with Stat6 /  BMMC extract. As shown in Fig. 5 A,
when 715 Stat6 was incubated with Stat6 /  BMMC ex-
tract, two bands were detected with anti-Stat6 (M200) anti-
body (lane 2). The upper band exhibited the same mobility
to the 715 Stat6 and the lower band exhibited the same mo-
bility to 65-kD Stat6. Similarly, the incubation of 695 Stat6
with Stat6 /  BMMC extract resulted in two bands of Stat6,
the original 695 Stat6 and the 65-kD Stat6 (Fig. 5 A, lane 4).
In contrast, the size of 673 Stat6 was smaller than the 65-kD
Stat6 and the 673 Stat6 was not cleaved by the Stat6 / 
BMMC extract (Fig. 5 A). These results indicate that the
cleavage site is located between aa 673 and 695 of Stat6.
65-kD Stat6 Functions as a Dominant-negative Molecule to
Stat6-mediated Transcription. To investigate the functional
property of 65-kD Stat6, we first examined the transcrip-
tional activity of 695 and 673 Stat6. COS7 cells were trans-
fected with 695 or 673 Stat6 in the presence of a Stat6-depen-
dent reporter construct (TPU474; reference 20) and the
luciferase activity was measured in the presence or absence
of IL-4 stimulation. As a control, COS7 cells were trans-
fected with WT Stat6 and stimulated with IL-4. In cells ex-
pressing WT Stat6, IL-4 enhanced the transcription of
TPU474 (Fig. 5 B). In contrast, the expression of 695 or
673 Stat6 did not enhance the IL-4–induced transcription
(Fig. 5 B). Moreover, when 695 (Fig. 5 C) or 673 Stat6
(Fig. 5 D) was coexpressed with WT Stat6, these mutants
inhibited the Stat6-dependent transcription of WT Stat6 in
a dose-dependent fashion. These results indicate that 695
and 673 Stat6 function as dominant-negative regulators to
Stat6-dependent transcription and thus suggest that 65-kD
Stat6 may also act as a dominant-negative molecule.
D685A and M686A Stat6 Are Resistant to the Stat6 Pro-
tease Activity. To address the role of Stat6 protease activity
in mast cells, we tried to identify a mutant Stat6 that was
resistant to the protease activity. Because Stat6 was cleaved
between aa 673 and 695 and the mobility of 65-kD Stat6
was approximately in the middle of 695 and 673 Stat6 (Fig.
5 A), we prepared a series of point mutants of Stat6 by sub-
stituting each residues to alanine. The sensitivity of these
mutants to the Stat6 protease activity was then examined
by the coincubation assay. Interestingly, two of these mu-
tants, D685A (aspartic acid at aa 685 to alanine) and
M686A Stat6 (methionine at aa 686 to alanine), were resis-
tant to the Stat6 protease activity (Fig. 6, A and B). In con-
trast, S683A and S684A Stat6 were as sensitive to the pro-
tease activity as WT Stat6 (Fig. 6 A).
We next examined the transcriptional activity of cleav-
age-resistant D685A and M686A Stat6. As shown in Fig. 6
C, D685A and M686A Stat6 exhibited a comparable tran-
scriptional activity upon IL-4 stimulation to that of WT
Stat6 in COS7 cells.
Retrovirus-mediated Expression of Cleavage-resistant D685A
Stat6 Prolongs the Nuclear Accumulation of Stat6 in IL-4–stim-
ulated Mast Cells. D685A Stat6 is resistant to the Stat6
protease activity (Fig. 6 A) but normal in its transcriptional
activity in COS7 cells lacking Stat6 protease activity (Fig. 6
Figure 5. Stat6 is cleaved between aa 673 and 695 by the Stat6 protease
and the resultant Stat6 functions as a dominant-negative molecule. (A)
COOH-terminal–truncated mutants of Stat6 (715, 695, or 673 Stat6)
were transfected to COS7 cells. Cell extracts from these cells were incu-
bated with or without Stat6 /  BMMC extract and blotted with anti-
Stat6 (M200) antibody. A representative blot from four independent ex-
periments is shown. (B) COS7 cells were transfected with 695, 673, or
WT Stat6 (as a control) in the presence of a Stat6-responsive reporter
construct, TPU474. 20 h after transfection, cells were stimulated with or
without IL-4 for an additional 12 h and the luciferase activity of TPU474
was measured by the dual luciferase reporter system. Data are means  
SD for four experiments. (C and D) Similar to B, COS7 cells were trans-
fected with WT Stat6 in the presence of the indicated amounts of either
(C) 695 or (D) 673 Stat6. Data are means   SD for four experiments.
Figure 6. D685A and M686A Stat6 are resistant to the Stat6 protease
activity. (A) Alanine substitutions of Stat6 (S683A, S684A, D685A, or
M686A Stat6) were transfected to COS7 cells. Cell extracts were then in-
cubated with or without Stat6 /  BMMC extract and blotted with anti-
Stat6 (M200) antibody. A representative blot from four independent ex-
periments is shown. (B) Relevant aa sequence of the putative cleavage site
of Stat6 is shown in comparison with a reported cleavage site of Stat5a
and Stat5b (17). (C) Similar to Fig. 5 B, COS7 cells were transfected with
D685A, M686A, or WT Stat6 and the luciferase activity of TPU474 was
measured in the presence or absence of IL-4. Data are means   SD for
four experiments.33 Suzuki et al.
C). Thus, we now have a tool to investigate the in vivo
role of the Stat6 protease activity in mast cells. First, we ex-
amined the kinetics of nuclear accumulation of D685A
Stat6 upon IL-4 stimulation in CFTL-15 cells, a murine
mast cell line that expresses 65-kD Stat6 (25). CFTL-15
cells were infected with either MSCV-C-Flag WT Stat6-
IRES-Thy1.1 or MSCV-C-Flag D685A Stat6-IRES-
Thy1.1 retrovirus and before and after IL-4 stimulation,
subcellular localization of transfected Stat6 was visualized
with anti-Flag antibody. In the absence of IL-4 stimulation,
both WT and D685A Stat6 localized in the cytoplasm (Fig.
7 A). When stimulated with IL-4 for 15 min, both WT and
D685A Stat6 similarly accumulated in the nucleus (Fig. 7
A). Interestingly, although WT Stat6 disappeared from the
nucleus 60 min after IL-4 stimulation, D685A Stat6 still ac-
cumulated in the nucleus (Fig. 7 A).
To exclude the possibility that the difference between
WT and D685A Stat6 in their kinetics of nuclear accu-
mulation results from the nuclear export rather than the
sensitivity to the proteolytic processing, the analogous ex-
periments were performed in the presence of a nuclear
export inhibitor, leptomycin B. Even in the presence of
leptomycin B, WT Stat6 disappeared from the nucleus of
CFTL-15 cells much faster than D685A Stat6 did (Fig. 7
A, bottom panels). In contrast, in COS7 cells that lacked
Stat6 protease activity, WT and D685A Stat6 exhibited
indistinguishable kinetics of subcellular distribution upon
IL-4 stimulation, and WT Stat6 still accumulated in the
nucleus of COS7 cells, even at 60 min (Fig. 7 B). As ex-
pected, leptomycin B similarly prolonged the nuclear ac-
cumulation of WT and D685A Stat6 in COS7 cells (Fig.
7 B). Taken together, these results suggest that proteolytic
processing of Stat6 by the Stat6 protease is involved in the
control of nuclear accumulation of Stat6 in living mast
cells.
Retrovirus-mediated Expression of D685A Stat6 Enhances
IL-4–induced Apoptosis and Growth Inhibition in Mast Cells.
We next investigated the physiological significance of the
Stat6 protease activity in mast cells. When CFTL-15 cells
were infected with control retrovirus (MSCV-IRES-
Thy1.1) and then cultured with IL-3 alone or IL-3 plus IL-
4, the number of apoptotic cells (annexin V  cells) was sig-
nificantly increased in cells cultured with IL-3 plus IL-4
than in those cultured with IL-3 alone (IL-3, 2.7   0.4%
vs. IL-3 plus IL-4, 8.7   2.1% annexin V  cells in Thy1.1 
cells; mean   SD; n   5 experiments; P   0.005; Fig. 8
A). These results are consistent with a previous finding that
IL-4 increases the apoptosis of IL-3–dependent mast cells
(10). Interestingly, IL-4–induced apoptosis of CFTL-15
cells was significantly increased by the expression of D685A
but not WT Stat6 (D685A Stat6, 16.2   2.8% vs. WT
Stat6 8.1   1.9%; n   5; P   0.005; Fig. 8 A). To exclude
Figure 7. Stat6 protease regu-
lates the nuclear accumulation of
Stat6 in mast cells. (A) CFTL-15
cells were infected with either
MSCV-C-Flag WT Stat6-IRES-
Thy1.1 retrovirus or MSCV-C-
Flag D685A Stat6-IRES-Thy1.1
retrovirus and infected (Thy1.1 )
cells were positively collected by
magnetic cell sorting. Before and
after IL-4 stimulation, subcellular
localization of transfected Stat6
was visualized by Cy3-conjugated
anti-Flag antibody. Their nuclei
were stained with 4 -6-Diami-
dino-2-phenylindole. Where in-
dicated, 10 ng/ml leptomycin B
was added to the culture to block
nuclear export. DAPI, 4 -6-Dia-
midino-2-phenylindole; LMB,
leptomycin B. (B) COS7 cells
were transiently transfected with
either C-Flag WT Stat6 or C-Flag
D685A Stat6 expression plas-
mids. Before and after IL-4 stimu-
lation, subcellular localization of
transfected Stat6 was visualized by
Cy3-conjugated anti-Flag antibody.34 Mast Cell–specific Cleavage of Stat6
the possibility that the difference resulted from the expres-
sion levels of D685A and WT Stat6, we examined the ex-
pression of retrovirus-mediated D685A and WT Stat6 by
blotting cytoplasmic extracts from infected (Thy1.1 ) cells
with anti-Flag antibody. As shown in Fig. 8 B, the expres-
sion levels of D685A and WT Stat6 were comparable in in-
fected CFTL-15 cells. These results suggest that the cleav-
age-resistant D685A Stat6 behaves as hyperfunctional Stat6
in CFTL-15 cells and the proteolytic processing of Stat6 is
involved in the negative regulation of Stat6-mediated sig-
naling in CFTL-15 cells.
Next, we examined the effect of D685A Stat6 on the
cell growth of IL-3–dependent BMMCs using bicistronic
retroviruses that coexpress GFP. Stat6 /  BMMCs were
infected with D685A Stat6 retrovirus, WT Stat6 retrovirus,
or control retrovirus, and then cultured with either IL-3
alone or IL-3 plus IL-4. The number of live infected mast
cells (GFP  c-kit  PI  cells) was then determined 3 and 7 d
later. As shown in Fig. 9 A (left), in the absence of IL-4
stimulation, no significant difference was observed in IL-3–
induced proliferation of BMMCs among these viruses. In
Stat6 /  BMMCs expressing control retrovirus, IL-4 in-
creased the number of IL-3–dependent BMMCs (Fig. 9 A).
In contrast, IL-4 decreased the number of Stat6 /  BMMCs
when these cells were infected with WT Stat6 retro-
virus (Fig. 9 A). Retrovirus-mediated expression of 673
Stat6 did not affect the IL-4–induced growth inhibition of
Stat6 /  BMMCs (unpublished data). Interestingly, IL-4–
mediated growth inhibition was significantly enhanced in
Stat6 /  BMMCs infected with D685A Stat6 retrovirus
compared with those infected with WT Stat6 retrovirus
(D685A Stat6, 32.4   15.7% vs. WT Stat6, 90.2   20.4%
of percent cell growth at day 7; n   5 experiments; P  
0.001; Fig. 9 A). Consistent with this finding, apoptotic
cells (annexin V  cells) were increased in D685A Stat6–
expressing BMMCs than WT Stat6–expressing BMMCs
(D685A Stat6, 12.5   3.1% vs. WT Stat6, 6.8   2.5%; n  
5; P   0.01). These results suggest that the Stat6 protease
activity is involved in the regulation of Stat6-dependent
cell death pathway in mast cells.
65-kD Stat6 Functions as a Dominant-negative Regulator in
Mast Cells. To determine whether 65-kD Stat6 func-
tions as a dominant-negative regulator in mast cells, we
examined the effect of retrovirus-mediated expression of
673 Stat6 on IL-4–induced growth inhibition of BMMCs.
In contrast to its apparent dominant-negative effect in
COS7 cells (Fig. 5 D), the dominant-negative effect of
673 Stat6 was not obvious in WT BMMCs (Fig. 9 B).
However, because WT BMMCs express abundant 65-kD
Stat6 in the nucleus after IL-4 stimulation (Fig. 3 C), it is
possible that the endogenously produced 65-kD Stat6
masks the effect of 673 Stat6 in this situation. To elimi-
nate the interference by the endogenously produced 65-
kD Stat6, we examined the effect of retrovirus-mediated
expression of 673 Stat6 on D685A Stat6–expressing
Stat6 /  BMMCs (Fig. 9 C). When 673 Stat6 retrovirus
was coinfected with D685A Stat6 retrovirus in Stat6 / 
BMMCs, 673 Stat6 reversed the effect of D685A Stat6 on
IL-4–induced growth inhibition of Stat6 /   BMMCs
(Fig. 9 C). These results suggest that 673 Stat6 functions as
a dominant-negative regulator in mast cells. Taken to-
gether with the data shown in Fig. 9 B, these results also
suggest that the endogenously produced 65-kD Stat6 may
function as a dominant-negative regulator on full-length
Stat6 in mast cells.
Retrovirus-mediated Expression of D685A Stat6 Enhances
IL-4–induced Down-regulation of IgE Receptors on Mast
Cells. It has recently been shown that IL-4 decreases the
expression of IgE receptors on mast cells in a Stat6-depen-
dent manner (11). Therefore, we examined the effect of
retrovirus-mediated expression of D685A Stat6 on the
levels of IgE receptors on BMMCs. Stat6 /  BMMCs
were infected with WT Stat6 retrovirus, D685A Stat6 ret-
rovirus, 673 Stat6 retrovirus, or control retrovirus, al-
lowed to grow for 3 d in the presence of IL-3, and then
cultured with either IL-3 alone or IL-3 plus IL-4 for 24 h.
The expression of IgE receptors on infected (GFP )
BMMCs was analyzed by flow cytometry. As shown in
Fig. 10, in the absence of IL-4 stimulation, no significant
differences were observed in the expression of IgE recep-
tors among these retrovirus-infected BMMCs. Consistent
with the previous report (11), IL-4 decreased the expres-
sion of IgE receptors in WT Stat6 virus–infected Stat6 / 
BMMCs (IgE-bindinglow cells, 25.3   5.5%; n   4; Fig.
10). Interestingly, IL-4–mediated down-regulation of IgE
receptors was significantly enhanced when Stat6 /  BMMCs
were infected with D685A Stat6 virus (IgE-bindinglow
cells, 53.5   6.8%; P   0.01), which suggests that D685A
Stat6 functions as hyperfunctional Stat6 in IL-4–induced
down-regulation of IgE receptors on BMMCs. In con-
trast, IL-4 did not decrease the expression of IgE receptors
on Stat6 /  BMMCs that were infected with 673 Stat6 or
control virus (Fig. 10), indicating that IL-4–induced
down-regulation of IgE receptors requires the transcrip-
tional activity of Stat6.
Figure 8. Retrovirus-medi-
ated expression of the cleavage-
resistant Stat6 increases IL-4–
induced apoptosis in CFTL-15
cells. (A) CFTL-15 cells were in-
fected with MSCV-C-Flag WT
Stat6-IRES-Thy1.1, MSCV-C-
Flag D685A Stat6-IRES-Thy1.1,
or MSCV-IRES-Thy1.1 (as a
control) retroviruses. Cells were
cultured in the presence of IL-3
for 2 d and then cultured with
IL-3 alone or IL-3 plus IL-4 for
an additional 3 d. The percent-
age of annexin V   cells in
Thy1.1  cells was then evaluated
by FACS®. Data are mean   SD
for five experiments. *, Signifi-
cantly different from the mean
value of MSCV-C-Flag WT Stat6-IRES-Thy1.1 infected cells; P   
0.005. (B) Anti-Flag and anti-Stat3 (as a control) blottings of sorted
Thy1.1  cells.35 Suzuki et al.
Discussion
In this study, we show a novel regulatory mechanism of
Stat6-mediated signaling in murine mast cells. We found
that when Stat6 was phosphorylated on IL-4 stimulation
and translocated to the nucleus, phosphorylated Stat6 was
cleaved by a nucleus-associated protease in BMMCs (Figs.
1 and 2). We also found that the cleaved 65-kD Stat6
lacked the COOH-terminal transactivation domain (Fig. 1)
and functioned as a dominant-negative molecule to Stat6-
mediated transcription (Fig. 5). Moreover, the retrovirus-
mediated expression of cleavage-resistant D685A Stat6
prolonged the nuclear accumulation of Stat6 upon IL-4
stimulation in mast cell line CFTL-15 cells but not in
COS7 cells that lack the protease activity (Fig. 7). Further-
more, the expression of D685A Stat6 enhanced IL-4–
induced apoptosis and growth inhibition in mast cells (Figs.
8 and 9). D685A Stat6 also enhanced IL-4–induced down-
regulation of IgE receptors in BMMCs (Fig. 10). Taken to-
gether, these results indicate that the proteolytic processing
of Stat6 is a lineage-specific negative regulatory mechanism
of Stat6-dependent signaling in mast cells.
We show that phosphorylated Stat6 is cleaved by the
Stat6 protease in the nucleus of mast cells and that the re-
sultant 65-kD Stat6 lacks the transcriptional activity and
functions as a dominant-negative molecule to Stat6-medi-
ated signaling. Stat6 was cleaved by the protease between
aa 673 and 695 of Stat6 (Fig. 5 A). Furthermore, we found
that alanine substitution of aspartic acid at 685 or methio-
nine at 686 of Stat6 was resistant to the Stat6 protease ac-
tivity (Fig. 6 A), which suggests that Stat6 is cleaved around
this region. Thus, the 65-kD Stat6 is apparently different
from the previously reported Stat6 isoforms in human fi-
broblast, Stat6b and Stat6c, which encode an NH2-terminal
truncation and an SH2 domain deletion, respectively, and
result from alternative splicing (27). Regarding the func-
tional property of 65-kD Stat6, we found that COOH-ter-
minal–truncated mutants of Stat6 at either aa 673 or 695
Figure 9. Retrovirus-mediated expression of D685A Stat6 enhances
IL-4–induced growth inhibition of Stat6 /  BMMCs. (A) Stat6 /  BMMCs
were infected with retroviruses of pMX-WT Stat6-IRES-GFP,
pMX-D685A Stat6-IRES-GFP, or pMX-IRES-GFP, and then cultured
with IL-3 alone (left) or IL-3 plus IL-4 (right). The number of live in-
fected BMMCs (GFP  c-kit  PI  cells) was determined at days 0, 3, and 7
using a hemocytometer and FACS®. Data are means   SD for five exper-
iments. *, significantly different from the mean value of pMX-WT Stat6-
IRES-GFP infected cells; P   0.001. (B) WT BMMCs were infected
with retroviruses of pMX-673 Stat6-IRES-GFP or pMX-IRES-GFP and
then cultured with IL-3 alone (left) or IL-3 plus IL-4 (right). The number
of live infected BMMCs was determined as described above. (C) Stat6 / 
BMMCs were doubly infected with GFP-labeled retroviruses (either
pMX-673 Stat6-IRES-GFP or pMX-IRES-GFP) and Thy1.1-labeled
retroviruses (either MSCV-C-Flag D685A Stat6-IRES-Thy1.1 or
MSCV-IRES-Thy1.1), and then cultured with IL-3 alone (left) or IL-3
plus IL-4 (right). The number of live doubly infected BMMCs (GFP 
Thy1.1  PI  cells) was determined at day 0, 3, and 7 using a hemocytom-
eter and FACS®. Data are means   SD for four experiments. *, Signifi-
cantly different from the mean value of pMX-IRES-GFP and/or
MSCV-C-Flag D685A Stat6-IRES-Thy1.1 infected cells; P   0.01.
Figure 10. D685A Stat6 enhances IL-4–induced down-regulation of
IgE receptors on Stat6 /  BMMCs. Stat6 /  BMMCs were infected with
retroviruses of pMX-WT Stat6-IRES-GFP, pMX-D685A Stat6-IRES-
GFP, pMX-673 Stat6-IRES-GFP, or pMX-IRES-GFP, and then cul-
tured with IL-3 alone or IL-3 plus IL-4 for 24 h. The expression of IgE
receptors on infected (GFP ) BMMCs was determined by FACS®. Rep-
resentative FACS® profiles from four independent experiments are shown.36 Mast Cell–specific Cleavage of Stat6
lost the transcriptional activity in a Stat6-dependent re-
porter assay (Fig. 5). Moreover, the coexpression of these
truncated mutants with full-length Stat6 inhibited the
Stat6-mediated transcription (Fig. 5) and growth inhibition
of mast cells (Fig. 9 C), suggesting that 65-kD Stat6 func-
tions as a dominant-negative regulator to Stat6-mediated
signaling. This observation is in agreement with the previ-
ous finding that COOH-terminal–truncated mutants of
Stat6 function as dominant-negative molecules in Stat6-
mediated transcription (20).
It has recently been shown that a ubiquitin-dependent
proteasome pathway regulates the turnover of Stat5 and
Stat6 in lymphoid cells (28). In the case of Stat5, Wang et al.
(28) clearly demonstrated that a relatively small, potentially
amphipathic   -helical region in the carboxyl-terminal of
Stat5 played an important role in the rapid turnover of Stat5
protein. However, the analogous region was not found in
Stat6 (28). In addition, we found that Stat6 cleaving activity
in mast cells was not inhibited by a proteasome inhibitor,
lactacystin (Fig. 3 A). Thus, the Stat6 cleaving activity in
mast cells seems independent of proteasome pathway.
On the other hand, we found that the Stat6 protease ac-
tivity in mast cells was inhibited by a serine protease inhib-
itor, AEBSF (Fig. 3 B) or PMSF (unpublished data), sug-
gesting that the protease may belong to serine protease
family. In addition, we found that the Stat6 protease activ-
ity was localized in the nucleus (Fig. 2 A). Interestingly,
these two properties are shared with the recently described
Stat5 protease in myeloid progenitors (15–17). It has also
been shown that Stat5 protease cleaves both Stat5a and
Stat5b at the COOH terminus (15–18). Although a num-
ber of properties are shared between the Stat6 protease ac-
tivity and the Stat5 protease activity, we believe that the
Stat6 protease activity is not identical to the Stat5 protease
activity for the following reasons. First, both Stat5a and
Stat5b were expressed as conventional forms in BMMCs
(Fig. 4 A). Second, Stat6 was expressed as 94-kD Stat6 in
FDC-P1 cells (unpublished data). Third, FDC-P1 cell ex-
tract cleaved Stat5 but not Stat6, whereas BMMC extract
cleaved Stat6 but not Stat5 (Fig. 4 B). Finally, the recogni-
tion sequence of Stat5 protease, ATYMDQA (17), is not
found in Stat6 (Fig. 6 B). Taken together, these results in-
dicate that the Stat6 protease activity differs from the Stat5
protease activity, although these two proteases may belong
to the same family. Thus, proteolytic inactivation of Stat
proteins by cell type–specific Stat proteases may be a gen-
eral mechanism in lineage-specific down-regulation of
Stat-mediated signaling.
At present, the mechanism underlying the restricted ex-
pression of Stat proteases and the regulation of their activi-
ties in a given cell type are unknown. Stat6 and Stat5 pro-
tease activity are restricted in mast cells and myeloid
progenitors, respectively (Fig. 1 and references 13–17). In
addition, we found that Stat6 protease activity was de-
tected in the nucleus of BMMCs (Fig. 2) and CFTL-15
cells (unpublished data) in the absence of IL-4 stimulation.
Moreover, Stat6 protease activity was even found in
Stat6 /  BMMCs (Fig. 2). These results indicate that the
Stat6 protease is in an active form in the nucleus of mast
cells and not dependent on the presence of its substrate.
However, because homeostatic regulation of the pro-
teolytic processing by serine proteases is achieved, in part,
through the interaction between a protease and a corre-
sponding endogenous serine protease inhibitor (serpin; ref-
erence 29), the loss of inhibitory activity of serpin may re-
sult in an imbalance between proteases and their inhibitors.
Thus, it is still possible that mast cell–specific proteolytic
processing of Stat6 may be achieved by the specific loss of
an inhibitor to the Stat6 protease activity in the nucleus of
mast cells.
It is clear from recent experiments using Stat6 /  mice
that Stat6 is not essential for IL-4–mediated proliferation of
mast cells (11). On the other hand, in some situations,
Stat6-mediated signaling has been shown to be essential for
the death-promoting effect of IL-4 on IL-3–dependent
mast cells by an undefined mechanism(s) (10). In agree-
ment with this observation, we found that the enforced
expression of WT Stat6 in Stat6 /  BMMCs diminished
the IL-4–induced cell growth (Fig. 9). Moreover, the
Stat6-mediated growth inhibition was significantly en-
hanced when cleavage-resistant D685A Stat6 was ex-
pressed in Stat6 /  BMMCs (Fig. 9). Therefore, our results
suggest that the proteolytic inactivation of Stat6 by the
Stat6 protease may prevent Stat6-mediated cell death of
mast cells.
Our results also indicate that Stat6-mediated gene ex-
pression is regulated in part by the Stat6 protease activity in
mast cells. Stat6 has been shown to be involved in the ex-
pression of a number of important genes in various cell
types (2). We found that IL-4–induced down-regulation of
IgE receptors on BMMCs was enhanced by the expression
of D685A Stat6 (Fig. 10). We also found that IL-4–induced
expression of CD23 was enhanced by the expression of
D685A Stat6 in BMMCs (unpublished data). Therefore,
our results suggest that in addition to the survival, the pro-
teolytic processing of Stat6 may also be involved in Stat6-
dependent gene regulation in mast cells.
Mast cells are not only important effector cells in acute
IgE-associated allergic reaction, but also contribute signif-
icantly to the protection from bacterial and parasitic infec-
tion (30). It has recently been shown that the activation of
mast cells by IL-4 is essential to expel gastrointestinal
nematode,  Trichinella spiralis (31), suggesting that mast
cells should survive in IL-4–rich environments to expel
parasites. Therefore, Stat6 protease system may play a role
in the prolongation of mast cell survival in this situation.
The further role of the Stat6 protease will be determined
when the protease is cloned and mice lacking the protease
are analyzed.
In conclusion, we have shown that the proteolytic pro-
cessing of Stat6 functions as a lineage-specific negative reg-
ulator of Stat6-dependent signaling in mast cells. Currently,
the mechanisms underlying the selective expression of Stat6
protease activity in mast cells are unclear. The protease ac-
tivity in mast cells appears to be independent of IL-4– and/
or Stat6-mediated signaling. In this regard, this regulatory37 Suzuki et al.
system differs from the SOCS/CIS/SSI system, in which
expression is induced in response to cytokine-induced Stat
activation (32). Thus, the Stat6 protease system may be
more potent than the SOCS/CIS/SSI system in abolishing
the early phase of Stat6-mediated signaling. It is suggested
that the Stat6 protease system might be applicable for the
treatment of allergic diseases by inducing the Stat6 protease
activity in T or B cells.
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